002932 明德生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入226,8080.53%350,062749,53710,530,2782,829,830
减:营业总成本333,2794.18%432,523720,1464,497,1341,120,303
    其中:营业成本153,52341.16%161,411342,7033,491,170707,026
               财务费用(1,646)-75.58%(9,556)5,194(34,938)(5,880)
               资产减值损失----(86,919)4,753(646,672)0
公允价值变动收益(1,150)-280.45%1,7374,5892,7600
投资收益74,808-4.65%133,703120,55035,120673
    其中:对联营企业和合营企业的投资收益----(1,251)(6,735)--(5,776)
营业利润(17,147)-120.84%41,187145,1945,079,8331,697,814
利润总额(5,278)-106.76%32,416139,8895,076,3971,694,557
减:所得税费用7,168-54.37%5,85170,673695,843247,869
净利润(12,446)-119.96%26,56569,2164,380,5541,446,688
减:非控股权益(25,962)39.77%(47,955)(5,710)172,05733,463
股东净利润13,516-83.30%74,52074,9264,208,4971,413,224

市场价值指针
每股收益 (元) *0.062-82.40%0.3300.33018.4609.950
每股派息 (元) *----1.2300.1205.2004.500
每股净资产 (元) *23.917-5.56%25.05725.91541.61526.591
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见--
回页顶
备注: *未调整数据
#只提供简体内容